<DOC>
	<DOCNO>NCT00098397</DOCNO>
	<brief_summary>This phase II trial study well FR901228 work treat patient metastatic breast cancer . Drugs use chemotherapy , FR901228 , work different way stop growth tumor cell , either kill cell stop dividing . FR901228 may also stop growth tumor cell block enzymes need cell growth</brief_summary>
	<brief_title>FR901228 Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy safety FR901228 ( depsipeptide ) patient metastatic breast cancer . SECONDARY OBJECTIVES : I . Determine clinical activity drug , term progression-free survival , patient . OUTLINE : This multicenter study . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 2.4-12.3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer Metastatic disease Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan The following consider measurable disease : Bone disease Pleural effusion Peritoneal effusion Must receive prior anthracycline ( doxorubicin epirubicin ) and/or taxane ( paclitaxel docetaxel ) adjuvant therapy advance disease Therapy highdose regimen bone marrow transplantation consider 1 prior regimen No know brain metastasis Hormone receptor status : Not specify Male female Performance status ECOG 01 Performance status Karnofsky 70100 % More 12 week Absolute neutrophil count ≥ 1,500/mm^3 WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal Creatinine clearance ≥ 60 mL/min QTc &lt; 500 msec No New York Heart Association class III IV congestive heart failure No myocardial infarction within past year No uncontrolled dysrhythmia No poorly control angina No significant cardiac disease No history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition FR901228 No active ongoing infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness No concurrent biologic agents No 1 prior chemotherapy regimen metastatic disease More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior FR901228 ( depsipeptide ) No concurrent chemotherapy Prior hormonal therapy metastatic disease adjuvant therapy allow More 4 week since prior radiotherapy recover No concurrent radiotherapy More 2 week since prior minor surgery recover More 4 week since prior major surgery recover Concurrent bisphosphonates allow provided therapy initiate ≥ 3 month ago No concurrent agent cause QTc prolongation No concurrent combination antiretroviral therapy HIVpositive patient No concurrent drug know histone deacetylase activity ( e.g. , valproic acid ) No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>